Lymphoma, Large B-Cell, Diffuse: all 1,432 studies
Page 3 of 15. Open to participants first (359), then studies with results posted, then the rest; newest registration first within each.
- GVM±R in Patients With Relapsed or Refractory Aggressive NHL.RecruitingNCT06244368Phase 2
- Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T TherapyRecruitingNCT06238648Phase 2
- Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ MalignanciesRecruitingNCT06227026Phase 1
- Preliminary Assessment of [18F]BL40 in PET/CT ScansRecruitingNCT06224309
- Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell LymphomaRecruitingNCT06220032Phase 3
- Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).RecruitingNCT06213636Phase 1/2
- CLIC-2201 for the Treatment of Relapsed/Refractory B Cell MalignanciesRecruitingNCT06208735Phase 1
- B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic MalignanciesRecruitingNCT06191887Phase 1
- CD30 Imaging in Diffuse Large B-cell LymphomaNot yet recruitingNCT06186986Phase 3
- Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL PatientsRecruitingNCT06176729Phase 2
- Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06164327Phase 1
- Characterization and Clinical Impact of the Gut Microbiota in LymphomaRecruitingNCT06161896
- AZA Combined With RCHOP in P53-mutated DLBCL.RecruitingNCT06158399Phase 2
- Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FLRecruitingNCT06151080Phase 2
- Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a SolutionRecruitingNCT06131801
- Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical ResearchRecruitingNCT06120166Early Phase 1
- Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFURecruitingNCT06116110
- A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell LymphomaRecruitingNCT06091865Phase 3
- A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCLRecruitingNCT06086197Phase 2
- CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic LeukemiaRecruitingNCT06081478Phase 2
- Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)RecruitingNCT06050694Phase 2
- Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell LymphomaRecruitingNCT06047197Phase 1
- A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell MalignanciesRecruitingNCT06045910Phase 1/2
- Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic NeoplasmsRecruitingNCT06043011
- Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCLRecruitingNCT06033820Phase 2
- Real-World Study of DLBCL With Different Genetic SubtypesRecruitingNCT06026488
- CD79b-19 CAR T Cells in Non-Hodgkin LymphomaRecruitingNCT06026319Phase 1
- A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.RecruitingNCT06022029Phase 1
- Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06015880Phase 1
- An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCLNot yet recruitingNCT06015464
- Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein ExpressionRecruitingNCT06005870Phase 2
- The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.Not yet recruitingNCT05990985Not applicable
- LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell MalignanciesRecruitingNCT05990465Phase 1
- A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)RecruitingNCT05984147Phase 1
- Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLRecruitingNCT05952024Phase 2
- Hypnosis: a Path to AppeasementRecruitingNCT05942885Not applicable
- Study of a Communication Training Intervention for Large B-Cell Lymphoma ProvidersRecruitingNCT05940272Not applicable
- Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT05940051Phase 2
- Lifestyles Implemented-Survivorship Care Plan In Lymphoma SurvivorsRecruitingNCT05934084Not applicable
- A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell LymphomaRecruitingNCT05933967Phase 2
- Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell LymphomaNot yet recruitingNCT05923879
- (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)Not yet recruitingNCT05923502
- A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic MalignanciesRecruitingNCT05908409Phase 1/2
- A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological TypesNot yet recruitingNCT05907447
- Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to TreatmentRecruitingNCT05890352Phase 2
- Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk FactorsNot yet recruitingNCT05887726Phase 2
- Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological MalignanciesRecruitingNCT05887167Phase 1
- A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCLNot yet recruitingNCT05883709
- Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)RecruitingNCT05875428Phase 2
- A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete RemissionNot yet recruitingNCT05874778Phase 2
- A Combination Study of CAR-T Therapy in r/r B-NHLRecruitingNCT05871684Phase 2
- Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCLNot yet recruitingNCT05863845Not applicable
- Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell LymphomaRecruitingNCT05852717Phase 2
- A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell MalignanciesRecruitingNCT05836896Phase 1
- Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis BiomarkersNot yet recruitingNCT05834426
- Frontline of ASCT in High-risk DLBCLRecruitingNCT05831865
- Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell LymphomaRecruitingNCT05826535Phase 1/2
- Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL PatientsRecruitingNCT05823701Phase 2
- Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell LymphomaRecruitingNCT05820841Phase 3
- Decitabine and Anti-PD-1 in R/R DLBCLRecruitingNCT05816746Phase 2
- Pro-miniCHOP-like Regimen for Treatment-naive Elderly PatientsRecruitingNCT05809180Not applicable
- Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell LymphomaRecruitingNCT05800405Early Phase 1
- A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell LymphomaRecruitingNCT05800366Phase 2
- A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell MalignanciesRecruitingNCT05780034Phase 1
- Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell TherapyRecruitingNCT05757219Phase 2
- Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIMOSA)Not yet recruitingNCT05746858
- Early Detection and Screening of Hematological Malignancies - SANGUINERecruitingNCT05735704
- Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical ResearchRecruitingNCT05715606Early Phase 1
- Chidamide in Patients With Recurrent and Refractory Diffuse Large bEnrolling by invitationNCT05690191
- Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaRecruitingNCT05672251Phase 2
- CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCLRecruitingNCT05659628Phase 1
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT05633615Phase 2
- A Compassionate Use (CU) Program of OdronextamabAvailableNCT05619367
- Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial RemissionNot yet recruitingNCT05596097Phase 2
- Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL PatientsRecruitingNCT05577364Phase 1/2
- Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell LymphomaNot yet recruitingNCT05575973Phase 2
- Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte MalignanciesRecruitingNCT05541341
- B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021RecruitingNCT05518383Phase 4
- A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCLRecruitingNCT05514327Not applicable
- Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell MalignanciesRecruitingNCT05487651Phase 1
- ChiCGB vs BEAM in High-risk or R/R LymphomasRecruitingNCT05466318Phase 3
- A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomaRecruitingNCT05444322Early Phase 1
- Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin LymphomaRecruitingNCT05432635Phase 1
- The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.RecruitingNCT05428670Phase 2
- Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell LymphomaRecruitingNCT05422066Phase 2
- Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasRecruitingNCT05389423Phase 1
- Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell LymphomaNot yet recruitingNCT05381506Phase 2
- Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell TherapyRecruitingNCT05377307
- Bio-CAR-T BS StudyRecruitingNCT05366569
- IKS03 in Patients With Advanced B Cell Non-Hodgkin LymphomasRecruitingNCT05365659Phase 1
- Genotype-guided Treatment in DLBCLRecruitingNCT05351346Phase 3
- Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell LymphomaRecruitingNCT05348213Phase 2
- Electronic MonitorIng of Events for dIffuse Large b Cell LYmphomaNot yet recruitingNCT05298293Not applicable
- ZR-CHOP in DLBCL With Specific Gene AbnormalityRecruitingNCT05290337Phase 2
- ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCLRecruitingNCT05290090Phase 2
- Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic LeukemiaRecruitingNCT05281809Phase 2
- First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOPNot yet recruitingNCT05280626Phase 2
- Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaRecruitingNCT05272384Phase 1
- R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS RelapseRecruitingNCT05257018Phase 2
- Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell LymphomaRecruitingNCT05256641Phase 1/2